JPMorgan downgraded Zimmer Biomet (ZBH) to Neutral from Overweight with a price target of $100, down from $115. The firm views the earnings report as a “step backwards” for Zimmer. Estimates are numbers moving lower due to a “mismatch” between management guidance and the underlying business trends, the analyst tells investors in a research note. JPMorgan says Zimmer’s 2025 organic sales growth guidance is moving lower, and likely to is Street 2026 forecasts. It cites the reduced growth outlook for the downgrade.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet downgraded to Neutral from Overweight at JPMorgan
- Zimmer Biomet Holdings: Hold Rating Amid Revenue Miss and Market Share Decline
- Zimmer Biomet Holdings: Mixed Q3 Performance and Narrowed Guidance Justify Hold Rating
- Zimmer Biomet Holdings: Strong Innovation Pipeline and Financial Health Justify Buy Rating Despite Recent Challenges
- Zimmer Biomet price target lowered to $110 from $118 at Stifel